Research groups

GC14 Cellular Therapy

The group Cellular Therapy is a consolidated group of IMIBIC that focuses its activity on clinical and translational research in advanced therapies, specifically in cell therapy and cell-gene therapy.

Regarding clinical research, in the last ten years we have participated in 10 independent clinical trials of cell therapy from cells derived from bone marrow in cardiovascular pathology (myocardial regeneration and peripheral vascular pathology), neurological diseases (stroke and multiple sclerosis), and transplant-related diseases (GVHD). In this context, the Cell Therapy Group is a central unit of cell production under GMP conditions that coordinates its activity with other IMIBIC groups in the development of new Advanced Therapy Medicinal Products (ATMPs) for various pathologies with a high sociosanitary impact.

Along with clinical research, we devote our research to the basic and translational aspects of new cellular therapies in intermediate or early stages of its development. In this sense, we actively collaborate with GENYO in preclinical models of cell-gene therapy in genetic diseases such as Wiskott-Aldrich, and in anti-leukemic immunotherapy with T-CAR lymphocytes. The group's PI Dr. Herrera is the coordinator of IMIBIC's participation in the ATMP Platform of the European Infrastructure for Translational Medicine – EATRIS.

Research Lines

Networks

Keywords

  • Stem cells
  • cell therapy
  • regenerative medicine
  • myocardial regeneration
  • therapeutic angiogenesis
  • cell-gene therapy
  • CAR-T cells

GC14 Cellular Therapy

Principal Investigator
Inmaculada Concepción Herrera Arroyo

Researchers
Rosa Ortega Salas

Post-Doctoral Researchers
Mª Dolores Carmona Luque
Macarena Centeno Haro
Rosario Jiménez Moreno
Vanesa Martín Palanco
Sonia Nogueras Martin

Pre-Doctoral Researchers
Lourdes Ortiz Espejo
Kristina Pavlovic

Technical Staff
Rosario Gutierrez Fernandez

Projects

Active projects

Regional

Herrera Arroyo, Inmaculada C. Estudio preclínico de la eficacia antileucémica de linfocitos T TCRKO con expresión inducible de un receptor antigénico quimérico (CAR) anti-CD19 y proporción controlada de poblaciones efectoras y memoria. Consejería de Salud. Junta de Andalucía. Reference: PE-0223-2018. 2019-2022.

National

Herrera Arroyo, I.C. Desarrollo preclínico de CAR-T anti CD19 universales con subpoblaciones predetrminadas de memoria y efectores y expresión inducible del CAR.Funding Agency: National Institute of Health Carlos III (ISCIII). Reference:PI18/01610

Publications

Publications 2019

Romero M, Suarez-de-Lezo J, Herrera C, Pan M, Lopez-Aguilera J, Suarez-de-Lezo J, Baeza-Garzon F, Hidalgo-Lesmes FJ, Fernandez-Lopez O, Martinez-Atienza J, Cebrian E, Martin-Palanco V, Jimenez-Moreno R, Gutierrez-Fernandez R, Nogueras S, Carmona MD, Ojeda S, Cuende N, Mata R. Randomised, double-blind, placebo-controlled clinical trial for evaluating the efficacy of intracoronary injection of autologous bone marrow mononuclear cells in the improvement of the ventricular function in patients with idiopathic dilated myocardiopath. BMC CARDIOVASCULAR DISORDERS. 2019; 19(1). Núm. art.:203.
IF: 1,947
Q: 3

Mancha F, Escudero-Martínez I, Zapata-Arriaza E, Vega-Salvatierra A, Cabezas JA, Lebrato L, Pardo B, De-La-Torre J, Zapata M, Escamilla V, Calderón-Cabrera C, Martín-Sánchez J, Valverde R, Aguera-Morales E, Herrera I, Delgado F, Gamero MÁ, Pérez-Sánchez S, Moya M, Espinosa R, Ortega-Quintanilla J, Gutierrez-Jarrin I, González-García A, Montaner J, Moniche F. Circulating microRNA after autologous bone marrow mononuclear cells (BM-MNCs) injection in ischemic stroke patients. J Investigative Med. 2019 Dec 17. pii: jim-2019-001161. doi: 10.1136/jim-2019-001161
IF: 1,994
Q: 2

Ciria R, Ayllon-Teran MD, Gonzalez-Rubio S, Gomez-Luque I, Ferrin G, Moreno A, Sanchez-Frias M, Alconchel F, Herrera C, Martin V, Sanchez-Hidalgo JM, Arjona-Sanchez A, Okuda Y, Cabrera I, Benavente B, Rodriguez MJ, Jurado-Martinez I, Duenas-Jurado JM, Robles-Arista JC, Rodriguez-Peralvarez M, Garcia MD, Lopez-Cillero P, Briceno J. Rescue of Discarded Grafts for Liver Transplantation by Ex Vivo Subnormothermic and Normothermic Oxygenated Machine Perfusion: First Experience in Spain. TRANSPLANTATION PROCEEDINGS. 2019; 51(1):20-24.
IF: 0,959
Q: 4

Bento L, Bastida JM, Garcia-Cadenas I, Garcia-Torres E, Rivera D, Bosch-Vilaseca A, De Miguel C, Martinez-Munoz ME, Fernandez-Aviles F, Roldan E, Chinea A, Yanez L, Zudaire T, Vaz CP, Espigado I, Lopez J, Valcarcel D, Duarte R, Cabrera R, Herrera C, Gonzalez-Porras JR, Gutierrez A, Solano C, Sampol A. Thrombopoietin Receptor Agonists for Severe Thrombocytopenia after Allogeneic Stem Cell Transplantation: Experience of the Spanish Group of Hematopoietic Stem Cell Transplant. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. 2019; 25(9):1825-1831.
IF: 3,796 
Q: 2

Main Publications 2018

Martinez MSA, Ruiz CR, Sanchez RS, Salas RO, Andreu ML, Garcia PA, Hernandez ME. C3 deposits worsens the prognosis in type III extracapillary glomerulonephritis. NEFROLOGIA. 2018; 38(2):213-219.
IF: 1,167  
Q: 4

Other Publications 2018

Rubio-Navarro A, Sanchez-Nino MD, Guerrero-Hue M, Garcia-Caballero C, Gutierrez E, Yuste C, Sevillano A, Praga M, Egea J, Roman E, Cannata P, Ortega R, Cortegano I, de Andres B, Gaspar ML, Cadenas S, Ortiz A, Egido J, Moreno JA. Podocytes are new cellular targets of haemoglobin-mediated renal damage. JOURNAL OF PATHOLOGY. 2018; 244(3):296-310.
IF: 6,253  
Q: 1

Garzon FB, Alvarez-Ossorio MP, Moreno MAR, Palanco VM, Arroyo CH, Conde JSDC. Coronary Flow Reserve and Ventricular Function Following Regenerative Treatment in Patients With Revascularized Acute Anterior Myocardial Infarction. REVISTA ESPANOLA DE CARDIOLOGIA. 2018; 71(5):344-350.
IF: 5,166  
Q: 1

Santamaria R, Diaz-Tocados JM, de Mier MVPR, Robles A, Salmeron-Rodriguez MD, Ruiz E, Vergara N, Aguilera-Tejero E, Raya A, Ortega R, Felsenfeld A, Munoz-Castaneda JR, Martin-Malo A, Aljama P, Rodriguez M. Increased Phosphaturia Accelerates The Decline in Renal Function: A Search for Mechanisms. SCIENTIFIC REPORTS. 2018; 8: Núm artículo 13701
IF: 4,122  
Q: 1

Herrera-Martinez AD, Gahete MD, Pedraza-Arevalo S, Sanchez-Sanchez R, Ortega-Salas R, Serrano-Blanch R, Luque RM, Galvez-Moreno MA, Castano JP. Clinical and functional implication of the components of somatostatin system in gastroenteropancreatic neuroendocrine tumors. ENDOCRINE. 2018; 59(2):426-437.
IF: 3,179  
Q: 2

Martin-Gomez MA, Caba-Molina M, Viciana-Martinez-Lage MJ, Ortega-Salas R, Sanchez-Crespo A, Soriano-Perez MJ, Gomez-Morales M. Collapsing glomerulonephritis with podocyte markers on hemophagocytic syndrome secundary to hepatosplenic T-cell lymphoma. BIOMEDICA. 2018; 38(4): No constan págs.
IF: 0,62  
Q: 4

Rodelo-Haad C, Gimenez RFD, Ortega R, Rodriguez M, Aljama P. Calcific arteriolopathy beyond chronic kidney disease. The role of hemochromatosis and vitamin K antagonists. CLINICAL CASES IN MINERAL AND BONE METABOLISM. 2018; 15(1):85-88.
IF: 0

Main Publications 2017

Martinez-Losada C, Martin C, Gonzalez R, Manzanares B, Garcia-Torres E, Herrera C. Patients lacking a Kir-ligand of HLA group C1 or C2 have a Better Outcome after Umbilical cord Blood Transplantation. FRONTIERS IN IMMUNOLOGY. 2017.8():-810.
IF: 6,429
Q: 1 

Carmona MD, Canadillas S, Romero M, Blanco A, Nogueras S, Herrera C. Intramyocardial bone marrow mononuclear cells versus bone marrow-derived and adipose mesenchymal cells in a rat model of dilated cardiomyopathy. CYTOTHERAPY. 2017.19(8):947-961.
IF: 3,203
Q: 2 

Other Publications 2017

Hormaechea-Agulla D, Gahete MD, Jimenez-Vacas JM, Gomez-Gomez E, Ibanez-Costa A, L-Lopez F, Rivero-Cortes E, Sarmento-Cabral A, Valero-Rosa J, Carrasco-Valiente J, Sanchez-Sanchez R, Ortega-Salas R, Moreno MM, Tsomaia N, Swanson SM, Culler MD, Requena MJ, Castano JP, Luque RM. The oncogenic role of the In1-ghrelin splicing variant in prostate cancer aggressiveness. MOLECULAR CANCER. 2017.16():-146.
IF: 6,204
Q: 1 

Hormaechea-Agulla D, Jimenez-Vacas JM, Gomez-Gomez E, Lopez FL, Carrasco-Valiente J, Valero-Rosa J, Moreno MM, Sanchez-Sanchez R, Ortega-Salas R, Gracia-Navarro F, Culler MD, Ibanez-Costa A, Gahete MD, Requena MJ, Castano JP, Luque RM. The oncogenic role of the spliced somatostatin receptor sst5TMD4 variant in prostate cancer. FASEB JOURNAL. 2017.31(11):4682-4696.
IF: 5,498
Q: 1  D: 1

Herrera-Martinez AD, Gahete MD, Sanchez-Sanchez R, Salas RO, Serrano-Blanch R, Salvaderra A, Hoflandi LJ, Luque RM, Galvez-Moreno MA, Castano JP. The components of somatostatin and ghrelin systems are altered in neuroendocrine lung carcinoids and associated to clinical-histological features. LUNG CANCER. 2017.109():128-136.
IF: 4,294
Q: 1 

Perez P, Rodriguez-Peralvarez M, Guerrero L, Gonzalez V, Sanchez R, Centeno M, Poyato A, Briceno J, Sanchez-Frias M, Montero JL, De la Mata M. Incidental hepatocellular carcinoma after liver transplantation: Prevalence, histopathological features and prognostic impact. PLOS ONE. 2017.12(4):-e0175010.
IF: 2,806
Q: 1 

Guerrero F, Cañadillas S, Ortega R, Herrera C, Aljama P. Relevance of protein content within the renal scaffold for kidney bioengineering and regeneration. Journal of Biomedical Science and Engineering (JBiSE). 2017; 11: 509-526.

Mesa-Quesada J, Roldan-Romero E, Lozano-Sanchez JA, Centeno-Haro M, Ortega-Salas RM, Bravo-Rodriguez F. Cervical paraspinal chordoma, a condition we should know. A case report. NEUROCIRUGIA. 2017.28(4):197-201.
IF: 0,548
Q: 4 

Robin M, Porcher R, Ciceri F, van Lint MT, Santarone S, Ehninger G, Blaise D, Gullbas Z, Muniz SG, Michallet M, Velardi A, Koster L, Maertens J, Sierra J, Selleslag D, Radujkovic A, Diez-Martin JL, Kanz L, Arroyo CH, Niederwieser D, Huang H, McDonald A, de Witte T, Koc Y, Kroger N.  Haploidentical transplant in patients with myelodysplastic syndrome. BLOOD ADVANCES. 2017.1(22):1876-1883.

Garcia-Cabezas S, Centeno-Haro M, Espejo-Perez S, Carmona-Asenjo E, Moreno-Vega AL, Ortega-Salas R, Palacios-Eito A. Intimal sarcoma of the pulmonary artery with multiple lung metastases: Long-term survival case. WORLD JOURNAL OF CLINICAL ONCOLOGY. 2017.8(4):366-370.

Clinical Research

Active in 2019

Ensayo clínico fase I / II multicéntrico aleatorizado, semicruzado, doble ciego, para la evaluación de la seguridad y factibilidad de la terapia sistémica con células mesenquimales derivadas de médula ósea autóloga en pacientes esclerosis múltiple.
PI: Dr. Eduardo Agüera Morales

Ensayo Clínico Fase II, Unicéntrico, Abierto, Controlado y Aleatorizado, para valorar la eficacia de la Infusión Intra arterial de células Mononucleadas de Médula Ósea Autóloga en Pacientes Con Ictus Isquémico.
PI: Dra. Inmaculada Concepción Herrera Arroyo

Multicenter Phase II Safety and preliminary Study of 2 dose regimens of HepaStem (Heterologous Human Adult Liver-derived Progenitor Cells) in Patients with Acute or Chronic Liver Failure.
PI: Dr. José Luis Montero Álvarez.

Ensayo clínico fase III, unicéntrico, abierto, controlado y aleatorizado, para valorar la eficacia de la infusión intracoronaria de células mononucleadas de médula ósea autóloga en pacientes con oclusión coronaria crónica y disfunción ventricular, previamente revascularizados.
PI: Dr. Manuel Pan Álvarez Ossorio.

Members

Team

Rosa Ortega Salas, Mª Dolores Carmona Luque, Macarena Centeno Haro, Rosario Jiménez Moreno, Vanesa Martín Palanco, Sonia Nogueras Martin, Lourdes Ortiz Espejo, Kristina Pavlovic, Rosario Gutierrez Fernandez